Review



two known pi3k inhibitors (byl719)  (J&K Scientific)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    J&K Scientific two known pi3k inhibitors (byl719)
    Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known <t>PI3K</t> inhibitors <t>(BYL719</t> and <t>BKM120)</t> in A549 and H661 cells.
    Two Known Pi3k Inhibitors (Byl719), supplied by J&K Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/two+known+pi3k+inhibitors+(byl719)/pi3k+akt+signaling+pathway+kit/pmc06643147-25-4-12
    Average 90 stars, based on 1 article reviews
    two known pi3k inhibitors (byl719) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer"

    Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

    Journal: International Journal of Biological Sciences

    doi: 10.7150/ijbs.32625

    Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.
    Figure Legend Snippet: Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.

    Techniques Used:

    Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.
    Figure Legend Snippet: Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.

    Techniques Used: Expressing

    Related Articles

    Expressing:

    Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer
    Article Snippet: Flupentixol and two known PI3K inhibitors (BYL719 and BKM120) were purchased from J&K Scientific Ltd. (Beijing, China). .. T



    Similar Products

    two known pi3k inhibitors (byl719)  (J&K Scientific)
    90
    J&K Scientific two known pi3k inhibitors (byl719)
    Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known <t>PI3K</t> inhibitors <t>(BYL719</t> and <t>BKM120)</t> in A549 and H661 cells.
    Two Known Pi3k Inhibitors (Byl719), supplied by J&K Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/two+known+pi3k+inhibitors+(byl719)/pi3k+akt+signaling+pathway+kit/pmc06643147-25-4-12
    Average 90 stars, based on 1 article reviews
    two known pi3k inhibitors (byl719) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.

    Journal: International Journal of Biological Sciences

    Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

    doi: 10.7150/ijbs.32625

    Figure Lengend Snippet: Flupentixol decreases lung cancer cell viability. (A) Flupentixol (2.5, 5, 10, 20, or 40 μM) inhibited the viability of four NSCLC cell lines (H661, A549, H520 and SK-SEM-1) in a dose-dependent manner but had little effect on BEAS-2B cells. The cells were treated with flupentixol for 24 hours, and MTT assays were performed to measure cell viability. (B) H661 and A549 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10, 20, or 40 μM) for 24, 48, and 72 hours. The inhibitory effect of flupentixol in lung cancer cells was in a dose- and time-dependent manner. (C) The 24-hour cytotoxicity of flupentixol was stronger than those of two known PI3K inhibitors (BYL719 and BKM120) in A549 and H661 cells.

    Article Snippet: Flupentixol and two known PI3K inhibitors (BYL719 and BKM120) were purchased from J&K Scientific Ltd. (Beijing, China).

    Techniques:

    Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.

    Journal: International Journal of Biological Sciences

    Article Title: The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

    doi: 10.7150/ijbs.32625

    Figure Lengend Snippet: Flupentixol specifically inhibits the PI3K/AKT pathway in lung cancer cells. (A) The expression levels of p-AKT (S473 and T308) and Bcl-2 were decreased by flupentixol in a dose-dependent manner. A549 and H661 cells were treated with increasing concentrations of flupentixol (2.5, 5, 10 or 15 μM) for 24 hours. Flupentixol had no effect on PI3K p110ɑ, t-AKT, p-ERK, t-ERK, VEGF, or MMP-9. (B) The inhibitory effects of two known PI3K inhibitors (BYL719 and BKM120) on the expression of p-AKT, t-AKT, and Bcl-2 in A549 and H661 cells.

    Article Snippet: Flupentixol and two known PI3K inhibitors (BYL719 and BKM120) were purchased from J&K Scientific Ltd. (Beijing, China).

    Techniques: Expressing